Skip to main content
Biophytis S.A. logo

Biophytis S.A. — Investor Relations & Filings

Ticker · ALBPS ISIN · FR001400OLP5 LEI · 9695008GIE061NBGU106 PA Professional, scientific and technical activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2023-11-27 Board/Management Inform…
Country FR France
Listing PA ALBPS

About Biophytis S.A.

https://www.biophytis.com/en/

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.

Recent filings

Filing Released Lang Actions
Biophytis appoints Yann Meunier and Bernard Lévy to its Scientific Advisory Board
Board/Management Information Classification · 99% confidence The document is explicitly titled and formatted as a "Press release" announcing the appointment of two individuals to the Scientific Advisory Board. It contains standard press release elements like a headline, date/location stamp, company boilerplate ('About BIOPHYTIS'), and a disclaimer section referencing forward-looking statements and SEC filings. This type of announcement, which is a formal communication to the public and investors about a specific corporate event (management/advisory board change), fits best under the category for Board/Management Information (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT).
2023-11-27 English
Biophytis nomme Yann Meunier et Bernard Lévy à son comité scientifique
Board/Management Information Classification · 98% confidence The document is a press release dated November 27, 2023, announcing the appointment of two new members, Dr. Yann Meunier and Professor Bernard Lévy, to Biophytis's scientific committee. This type of announcement concerns changes in key personnel or advisory bodies within the company, specifically related to management/advisory structure. This aligns directly with the definition for Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management (which often extends to key advisory committees like the scientific committee in biotech firms). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2023-11-27 French
Biophytis announces the success of its capital increase with preferential subscription rights for approximately €1.96 million
Capital/Financing Update Classification · 99% confidence The document is an announcement titled "Biophytis announces the success of its capital increase with preferential subscription rights for approximately €1.96 million". It details the results of a capital increase involving the issuance of new shares and warrants (ABSARs), including subscription figures, impact on share capital, and settlement dates. This content directly relates to fundraising, financing activities, and changes in capital structure. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific corporate finance event.
2023-11-20 English
Biophytis annonce le succès de son augmentation de capital avec maintien du droit préférentiel de souscription pour un montant d’environ 1,96 M€
Capital/Financing Update Classification · 98% confidence The document is a press release titled "Biophytis annonce le succès de son augmentation de capital avec maintien du droit préférentiel de souscription..." (Biophytis announces the success of its capital increase with maintenance of the preferential subscription right...). It details the completion of a financing operation, including the amount raised (€1.96 M), the subscription results, the resulting capital structure, and the impact on existing shareholders. This content directly relates to fundraising, financing activities, and capital structure changes. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not an Earnings Release (ER), Interim Report (IR), or a formal regulatory filing like a 10-K, but a specific announcement about a capital event.
2023-11-20 French
Biophytis announces receipt of Nasdaq Notice
Delisting Announcement Classification · 99% confidence The document is a press release from Biophytis announcing the receipt of a Nasdaq notification letter regarding non-compliance with the minimum bid price requirement. This is a regulatory announcement concerning the company's listing status on an exchange. Since it does not fit into specific categories like delisting (as it is a notice of deficiency, not a final delisting) or other financial reporting categories, it falls under the general regulatory filing category.
2023-11-17 English
Biophytis reçoit une notification du Nasdaq
Regulatory Filings Classification · 99% confidence The document is a press release dated November 17, 2023, announcing that Biophytis received a 'Letter of Notification' from Nasdaq because its American Depositary Shares (ADSs) closed below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). This is an official notification regarding a compliance deficiency with a stock exchange listing requirement. This type of specific regulatory compliance update, which is not a standard periodic report (like 10-K or IR) or a general regulatory filing (RNS), fits best under the category of Legal Proceedings Report (LTR) if it involves regulatory action or, more broadly, a specific regulatory notice. However, since it deals with a specific regulatory compliance issue (delisting risk/notice) that is not explicitly covered by other codes like DIRS, DIV, or DLST (which is a final delisting announcement, not a warning letter), it is best classified as a general Regulatory Filing (RNS) as it is a formal announcement of a regulatory event. Given the options, LTR covers legal/regulatory actions, but RNS is the designated fallback for miscellaneous regulatory announcements. Since this is a direct communication about a regulatory deficiency notice, RNS is the most appropriate general regulatory category available, although it is a very specific type of regulatory communication.
2023-11-17 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.